Drug intelligence / Profile preview

CD19-CAR lentiviral vector

Development stage
Unknown
Lead developer
Ospedale Pediatrico Bambino Gesù
Modality
Cell Therapies, Gene Therapies
Administration
Intravenous
01

Overview

CD19-CAR lentiviral vector is a gene therapy tool used to genetically engineer T cells to express a chimeric antigen receptor (CAR) directed against the human CD19 antigen. The vector is typically a self-inactivating (SIN) lentivirus, often pseudotyped with the vesicular stomatitis virus G glycoprotein (VSV-G), which delivers a transgene cassette encoding an anti-CD19 single-chain variable fragment (scFv) linked to intracellular signaling domains such as 4-1BB (CD137) or CD28 and the CD3ζ chain. Once transduced, the patient's T cells (CAR-T cells) can specifically recognize and eliminate CD19-expressing B cells. This platform is widely utilized in the development of therapies for B-cell malignancies, including acute lymphoblastic leukemia (ALL) and B-cell lymphomas, as well as for refractory systemic autoimmune diseases where B-cell depletion is therapeutic.

Other names
CD19 CAR LVVCD-19 CAR LVVCD 19 CAR LVVCD19 chimeric antigen receptor-based lentiviral vectorCD-19 chimeric antigen receptor-based lentiviral vectorCD 19 chimeric antigen receptor-based lentiviral vector
02

Targets

Beyond the preview

Go deeper on CD19-CAR lentiviral vector.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on CD19-CAR lentiviral vector.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call